Welcome to our dedicated page for Aktis Oncology news (Ticker: AKTS), a resource for investors and traders seeking the latest updates and insights on Aktis Oncology stock.
Aktis Oncology, Inc. reports clinical-stage oncology developments centered on targeted radiopharmaceuticals for solid tumors. The company’s miniprotein radioconjugate platform supports AKY-1189, a Nectin-4 program with potential across urothelial, breast, non-small cell lung, colorectal, cervical, and head and neck cancers, and AKY-2519, a B7-H3 program for prostate, lung, colorectal, and other solid tumors.
Recurring updates include FDA actions such as IND clearances and Fast Track designation, clinical-trial initiations, imaging and dosimetry data presentations, business and financial results, investor-conference participation, and board and committee changes. News also covers Aktis’ collaboration with Eli Lilly and Company to develop radioconjugates outside its proprietary pipeline.
Aktis Oncology (NASDAQ:AKTS) announced FDA clearance of IND applications for AKY-2519 (imaging [64Cu] and therapeutic [225Ac]) and plans a Phase 1b trial starting mid-2026. The company reported full-year 2025 results, pro forma cash of $562.1M after a January 2026 IPO, collaboration revenue of $6.5M, and continued investment in AKY-1189 and early programs.
Key near-term milestones include AKY-1189 preliminary data in Q1 2027, AKY-2519 imaging results mid-2026, GMP facility H2 2026 readiness, and two early programs targeting IND-enabling work in Q1 2027.
Aktis Oncology (NASDAQ:AKTS) announced that President and CEO Matthew Roden, Ph.D., will present at two investor conferences in March 2026: TD Cowen on March 3 and Leerink Partners on March 9.
Live webcasts will be available via the company's Investors site and archived replays will remain for about 90 days after each conference.
Aktis Oncology (NASDAQ:AKTS) said the U.S. FDA granted Fast Track designation to AKY-1189 for adult patients with locally advanced or metastatic urothelial cancer who progressed after prior systemic therapies. AKY-1189 is an actinium-225 miniprotein radioconjugate targeting Nectin-4, which is expressed in approximately 80–90% of urothelial cancers.
Aktis is enrolling a multi-site Phase 1b trial (NCT07020117) across multiple Nectin-4 tumor types and expects to present preliminary Part 1 results in Q1 2027. Fast Track may enable more frequent FDA interactions and rolling BLA submission eligibility.
Aktis Oncology (NASDAQ: AKTS) closed an upsized initial public offering of 17,650,000 shares at $18.00 per share on January 12, 2026, and the underwriters fully exercised an option to purchase an additional 2,647,500 shares at the same price, with that sale expected to close on January 14, 2026, subject to customary conditions.
The aggregate gross proceeds including the overallotment are expected to be approximately $365.4 million before underwriting discounts, commissions and offering expenses. Aktis began trading on the Nasdaq Global Select Market on January 9, 2026 under the ticker AKTS.
Vida Ventures applauded Aktis Oncology (Nasdaq: AKTS) on entering the public markets after an IPO that raised $318 million. Vida said it co-led Aktis’ Series A, remained a long‑term investor and was the company’s second‑largest shareholder pre‑IPO, with Helen Kim serving on the Aktis board since 2021. Vida co‑founder Brian Goodman served as Aktis’ founding COO and later CBO. Vida highlighted Aktis’ pipeline led by AKY-1189 (actinium-225, Nectin-4) and AKY-2519 (B7-H3), prior private funding of approximately $346 million, and a strategic collaboration with Eli Lilly that Vida described as a deal valued up to $1.2 billion.